NCT05810922

Brief Summary

The tree that produces the arbutus berry, the strawberry tree, scientific name Arbutus unedo L., belongs to the family of Ericaceae. It exists in almost all of Southern Europe in arid and siliceous lands, in woods and forests and is very common in Portugal. Known for its use in the production of liqueurs and brandy, the arbutus berry is a fruit that can be consumed in nature or incorporated in the preparation of other foods. Arbutus berry has been attributed some properties beneficial to health given its low caloric value and its high content of vitamin C and flavonoids, which is why it is considered a good source of antioxidants. Arbutus has a high carbohydrate content (70-80% dry weight) with a relevant fiber fraction (10-30%), constituting an interesting source of vegetable protein (1-9%) and lipids (2-3%). Given this interesting nutritional composition, the hypothesis is that a daily consumption of this fruit can have an impact in health outcomes such as microbiota modulation and an improvement of metabolic parameters.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 8, 2022

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 22, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 22, 2022

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 30, 2023

Completed
14 days until next milestone

First Posted

Study publicly available on registry

April 13, 2023

Completed
Last Updated

April 13, 2023

Status Verified

March 1, 2023

Enrollment Period

1 month

First QC Date

March 30, 2023

Last Update Submit

March 30, 2023

Conditions

Keywords

adipokinesarbutus berrygut microbiotainflammatory cytokinesshort chain fatty acidstrawberry tree

Outcome Measures

Primary Outcomes (2)

  • Changes in gut microbiota characterization

    Difference in gut microbiota taxonomic characterization, from baseline to the end of intervention

    14 days

  • Changes in gut microbiota diversity

    Difference in gut microbiota Shannon index, from baseline to the end of intervention

    14 days

Secondary Outcomes (14)

  • Changes in fasting glucose

    14 days

  • Changes in HOMA-IR

    14 days

  • Changes in HDL cholesterol

    14 days

  • Changes in total cholesterol

    14 days

  • Changes in LDL cholesterol

    14 days

  • +9 more secondary outcomes

Study Arms (2)

50 g arbutus berry

EXPERIMENTAL

consumption of 50 g arbutus berry/day for 14 days

Other: arbutus berry

200 g arbutus berry

EXPERIMENTAL

consumption of 200 g arbutus berry/day for 14 days

Other: arbutus berry

Interventions

consumption of 50 g arbutus berry/day or 200 g arbutus berry/day for 14 days

200 g arbutus berry50 g arbutus berry

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Caucasian.
  • Age between 18 and 50 years.
  • Filling informed consent.
  • Body mass index (BMI) between 18,5 kg/m2 and 25 kg/m2.

You may not qualify if:

  • Arbutus berry sensibility.
  • Arbutus berry daily consumption in the month before the study begin.
  • Having taken antibiotics within the 6 months prior to beginning the study.
  • Use of pro/prebiotics or fiber as a dietary supplement or any food/molecule that modifies intestinal transit time 6 weeks before recruitment.
  • Use of laxative 6 weeks before recruitment.
  • Specific nutritional therapy (e.g. high protein).
  • Excessive alcohol consumption.
  • Smoking.
  • Diagnosis of gastrointestinal pathology, hormonal or thyroid pathology, autoimmune diseases, chronic use of corticosteroids, psychiatric disease or Diabetes Mellitus.
  • Use of proton pump inhibitors, antidiabetic drugs, insulin, or statins.
  • Pregnant or breastfeeding.
  • Participation in another clinical trial within the last 3 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nova Medical School Universidade Nova de Lisboa

Lisbon, 1169-056, Portugal

Location

MeSH Terms

Conditions

Feeding Behavior

Condition Hierarchy (Ancestors)

Behavior, AnimalBehavior

Study Officials

  • Ana Faria, PhD

    Universidade Nova de Lisboa

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: one group consuming 50 g of arbutus berry/day one group consuming 200 g of arbutus berry/day
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 30, 2023

First Posted

April 13, 2023

Study Start

November 8, 2022

Primary Completion

December 22, 2022

Study Completion

December 22, 2022

Last Updated

April 13, 2023

Record last verified: 2023-03

Data Sharing

IPD Sharing
Will not share

Locations